GO:0005579 membrane attack complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005579 (membrane attack complex, MAC) is a pore-forming protein complex assembled from complement components C5b, C6, C7, C8, and multiple C9 molecules on target cell membranes.
• MAC assembly proceeds sequentially: C5b binds C6, then C7, inserting into the lipid bilayer; C8 docks and recruits C9, which polymerizes into a ring that forms the lytic pore.
• The MAC is a key effector of the terminal complement pathway and directly lyses Gram-negative bacteria, while on host cells it can trigger inflammation and tissue damage.
• CD59 is the principal membrane inhibitor of MAC, blocking C9 polymerization and preventing bystander lysis; its structural basis has been resolved.
• Soluble MAC (sC5b-9) in plasma is a widely used biomarker of complement activation in kidney disease, autoimmune disorders, and other conditions.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of MAC components and regulators in human cells and animal models.
Description
The membrane attack complex (MAC), defined by the Gene Ontology term GO:0005579, is a protein complex produced by sequentially activated components of the complement cascade that inserts into a target cell membrane and forms a pore, leading to cell lysis via ion and water flow. It is the terminal effector of the complement system and is composed of complement proteins C5b, C6, C7, C8, and C9. The MAC is essential for innate immune defense against Gram-negative bacteria, but when misdirected or insufficiently regulated it can damage host tissues and drive inflammatory disease. For researchers, GO:0005579 provides a precise ontological anchor for studying complement-mediated lysis, membrane pore formation, and the regulation of terminal complement activity. The complex is not a static entity; it assembles stepwise on membranes and is controlled by inhibitors such as CD59 and soluble regulators. Understanding MAC biology therefore requires integrating structural, biochemical, and genetic approaches. This article summarizes the authoritative QuickGO definition, the sequential assembly mechanism, the key protein components, and the experimental models, including CRISPR-based methods, that are used to interrogate MAC function in health and disease.
membrane attack complex At A Glance
| GO ID | GO:0005579 |
|---|---|
| GO term | membrane attack complex |
| Ontology | cellular_component |
| Synonym | MAC; TCC; terminal complement complex; membrane attack complex protein alphaM chain; membrane attack complex protein beta2 chain |
| Major function | Pore formation in target cell membranes leading to cell lysis via ion and water flow |
| Core components | C5b, C6, C7, C8 (alpha, beta, gamma), and multiple C9 molecules |
| Assembly trigger | Activation of the terminal complement pathway and cleavage of C5 |
| Key regulator | CD59 (membrane inhibitor) and soluble inhibitors such as clusterin and vitronectin |
| Soluble form | sC5b-9 (soluble MAC) detectable in plasma as a complement activation biomarker |
What Is GO:0005579?
GO:0005579 (membrane attack complex) is a cellular component defined as a protein complex produced by sequentially activated components of the complement cascade inserted into a target cell membrane and forming a pore leading to cell lysis via ion and water flow. In practice, the MAC is a hetero-oligomeric assembly of complement proteins C5b, C6, C7, C8, and C9 that creates a transmembrane channel.
Why Is membrane attack complex Important in Cell Biology?
The membrane attack complex is important because it is the terminal, lytic effector of complement and a central mechanism of innate immunity against Gram-negative bacteria, while also being a major cause of host tissue injury in inflammatory and autoimmune diseases. Its activity is tightly regulated, and dysregulation contributes to kidney disease, neurodegeneration, and other complement-mediated pathologies. Because MAC formation is a sequential, membrane-dependent process, it is an attractive target for therapeutic intervention and a rich subject for genetic and structural studies.
• Directly lyses Gram-negative bacteria by disrupting the bacterial cell envelope.
• Serves as the terminal effector of the complement cascade, linking innate immune activation to membrane damage.
• Deposits in kidney tissue in both healthy and diseased states, serving as a marker of complement-mediated renal injury.
• Acts as an inflammatory trigger, stimulating cells even at sublytic doses.
• Is regulated by CD59, whose structure explains how MAC pore formation is blocked.
• Soluble MAC (sC5b-9) is a clinically used biomarker of complement activation.
• Provides a target for therapeutic inhibition in complement-driven diseases.
• Its assembly mechanism informs the design of pore-forming proteins and nanobiotechnology.
What Happens During membrane attack complex?
Initiation by C5b
In simple terms: The complement cascade cuts C5, and the resulting C5b fragment starts the assembly line.
The membrane attack complex is initiated when complement activation leads to cleavage of C5 and generation of C5b, which becomes the nucleus for assembly of the terminal complement complex. C5b is transiently capable of binding C6, and this interaction stabilizes the nascent complex and commits it to the terminal pathway.
Assembly of C5b-7 and membrane insertion
In simple terms: C5b grabs C6 and C7, and the trio inserts into the target membrane.
C5b binds C6 to form C5b-6, which then binds C7; the resulting C5b-7 complex exposes a hydrophobic site that inserts into the lipid bilayer of the target membrane. This membrane insertion is a key step that anchors the growing complex and prepares it to recruit C8.
Recruitment of C8 and C9 polymerization
In simple terms: C8 docks onto the complex and brings in many C9 molecules that form a ring-shaped pore.
C8 binds to membrane-inserted C5b-7, and the C8 alpha subunit penetrates the membrane, forming a small channel. C8 then recruits multiple C9 molecules, which unfold and polymerize into a ring-like structure that completes the transmembrane pore. The polymerized C9 ring is the structural basis for ion and water flow that leads to cell lysis.
Pore formation and cell lysis
In simple terms: The finished pore lets ions and water rush in, causing the target cell to burst.
The fully assembled MAC forms a pore that disrupts membrane integrity, allowing ion and water flow that leads to osmotic lysis of the target cell. On Gram-negative bacteria, MAC damages the cell envelope and kills the organism. On host cells, sublytic MAC can also trigger inflammatory signaling without causing immediate lysis.
Regulation by CD59 and soluble inhibitors
In simple terms: CD59 and other inhibitors put a brake on the pore-forming machine to protect host cells.
CD59 is a glycosylphosphatidylinositol-anchored membrane inhibitor that binds to C8 and C9 and blocks C9 polymerization, preventing MAC pore formation on host cells. Soluble forms of MAC (sC5b-9) are generated when the complex is formed in the fluid phase or shed from membranes, and these are detectable in plasma as markers of complement activation. Additional soluble regulators such as clusterin and vitronectin also limit MAC assembly and insertion.
Key Genes Involved in GO:0005579 membrane attack complex
The membrane attack complex is built from a defined set of complement genes and is controlled by specific regulators; the table below lists the major protein-coding genes and their roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C5 | Source of C5b, the initiating fragment of MAC assembly | Target for complement inhibition; knockout models block MAC formation |
| C6 | Binds C5b to form C5b-6, essential for assembly | Deficiency causes susceptibility to Neisseria; used in assembly studies |
| C7 | Binds C5b-6 and inserts into membrane | Deficiency linked to recurrent infections; model for membrane insertion |
| C8A | Alpha subunit of C8; penetrates membrane | Mutations cause C8 deficiency; structural studies of pore formation |
| C8B | Beta subunit of C8; binds C5b-7 | Deficiency impairs MAC; used in complement genetics |
| C8G | Gamma subunit of C8; stabilizes C8 | Less studied; potential modifier of MAC activity |
| C9 | Polymerizes to form the lytic pore | Central to pore formation; knockout abolishes lysis |
| CD59 | Membrane inhibitor of MAC; blocks C9 polymerization | Key regulator; knockout increases MAC-mediated damage |
| CLU | Clusterin; soluble inhibitor of MAC assembly | Modulates fluid-phase MAC; biomarker studies |
| VTN | Vitronectin; soluble inhibitor of MAC | Regulates MAC in plasma; relevant to complement therapeutics |
| CFH | Complement factor H; regulates alternative pathway upstream of MAC | Polymorphisms linked to kidney disease |
| CFI | Complement factor I; cleaves C3b and regulates cascade | Deficiency leads to uncontrolled complement activation |
| C3 | Central complement component upstream of C5 | Knockout blocks all terminal pathway activity |
| C4 | Complement component upstream of C3 | Relevant to classical pathway activation |
| C1Q | Initiates classical pathway | Autoimmunity and complement activation studies |
| MBL2 | Initiates lectin pathway | Innate immune recognition and MAC activation |
| CR1 | Complement receptor 1; regulates C3/C5 convertases | Modulates MAC formation on host cells |
| CD55 | Decay-accelerating factor; regulates complement convertases | Indirectly limits MAC assembly |
How Is membrane attack complex Regulated?
MAC assembly is regulated at multiple levels. CD59 directly binds C8 and C9 and prevents C9 polymerization, thereby blocking pore formation on host membranes. Soluble inhibitors such as clusterin and vitronectin bind to nascent C5b-7 and prevent membrane insertion, generating soluble sC5b-9. Upstream complement regulators, including factor H, factor I, CR1, and CD55, control the convertases that generate C5b and thus indirectly limit MAC formation. The balance between activation and inhibition determines whether MAC causes lysis, sublytic inflammation, or is safely cleared as sC5b-9.
membrane attack complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C5 | Complement-mediated inflammatory disease; target of anti-C5 therapy | C5 knockout cell line; point mutation to block cleavage |
| C9 | Deficiency associated with recurrent infections | C9 knockout in human cells; knock-in of patient variants |
| CD59 | Paroxysmal nocturnal hemoglobinuria-like complement damage | CD59 knockout; overexpression to test protection |
| CFH | Atypical hemolytic uremic syndrome and kidney disease | Knock-in of risk variants; knockout in renal cells |
| C6 | Terminal complement deficiency and infection susceptibility | C6 knockout; complement activation assays |
MAC in kidney disease
Deposition of the membrane attack complex is observed in healthy and diseased human kidneys, and MAC is implicated in complement-mediated renal injury such as glomerulonephritis and transplant rejection. Soluble MAC (sC5b-9) in plasma and urine is used as a biomarker of complement activation in these conditions.
MAC in inflammatory and autoimmune disorders
Sublytic MAC acts as an inflammatory trigger, activating cells and contributing to tissue damage in autoimmune and inflammatory diseases. Therapeutic strategies targeting terminal complement components aim to reduce MAC-mediated pathology.
MAC in bacterial infection
The MAC is a primary defense against Gram-negative bacteria, and its assembly on the bacterial envelope causes lethal membrane damage. Deficiencies in terminal complement components increase susceptibility to infections, particularly Neisseria species.
From membrane attack complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of C9 abolish MAC pore formation? | C9 knockout cell line |
| Can a point mutation in C5 prevent C5b generation? | C5 point-mutation knock-in |
| Does CD59 overexpression protect host cells from MAC? | CD59 overexpression cell model |
| How does a disease-associated CFH variant affect MAC deposition? | CFH knock-in of patient variant |
| Can tagged C9 be used to track pore assembly? | Tagged knock-in of C9 |
| Which genes modify MAC-mediated lysis? | CRISPR library screening in complement-challenged cells |
How to Study the membrane attack complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test requirement of C5, C6, C7, C8, C9 for MAC |
| CRISPR knock-in | Precise variant introduction | Model disease-associated complement variants |
| ELISA for sC5b-9 | Soluble MAC levels | Biomarker of complement activation |
| Flow cytometry | Membrane MAC deposition | Quantify MAC on cell surfaces |
| Hemolytic assay | Complement-mediated lysis | Functional test of MAC pore formation |
| Bacterial killing assay | MAC-mediated bacterial death | Study defense against Gram-negative bacteria |
| Immunohistochemistry | Tissue MAC deposition | Kidney and other tissue biopsies |
| Structural biology (cryo-EM) | MAC and CD59 structures | Understand pore and inhibition mechanisms |
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of MAC component and regulator genes in human cells. For example, C9 knockout cells can be challenged with complement to measure loss of lysis, while CD59 overexpression can test protection.
Protein detection and quantification
Western blotting, ELISA for sC5b-9, and flow cytometry can quantify MAC components and soluble MAC in plasma or cell supernatants. These methods are essential for linking genotype to complement activation status.
Functional lysis assays
Complement-mediated lysis assays using sheep erythrocytes or Gram-negative bacteria measure MAC pore function directly. Combining these assays with genetic perturbations reveals which components are required for lysis.
Imaging and structural approaches
Electron microscopy and structural biology have revealed the ring-shaped C9 pore and the inhibitory mechanism of CD59. Imaging of MAC deposition in tissues, such as kidney biopsies, provides spatial information on complement activation.
How CRISPR Can Be Used to Study GO:0005579 membrane attack complex
Knockout
CRISPR knockout of MAC components such as C9 or C5 abolishes pore formation and provides a clean genetic background to test complement-mediated lysis. Knockout of CD59 increases sensitivity to MAC, demonstrating its regulatory role.
Point Mutation
Point mutations can be introduced into complement genes to model disease-associated variants or to block specific cleavage sites, allowing precise structure-function analysis of MAC assembly.
Knock-in
Knock-in of tagged or patient-derived alleles enables tracking of MAC components in live cells and study of variant effects on complement activation.
Overexpression
Overexpression of CD59 or soluble inhibitors can protect cells from MAC-mediated lysis and is used to test therapeutic strategies.
How EDITGENE Supports membrane attack complex Research
Researchers studying membrane attack complex-related genes often need to determine whether a candidate gene is causally involved in MAC assembly, regulation, or disease. EDITGENE provides the full suite of CRISPR cell model services to enable such causal experiments in relevant human cell types.
Contact EDITGENE today to design your custom CRISPR model for membrane attack complex research.
Frequently Asked Questions About membrane attack complex
What is the membrane attack complex (GO:0005579)?
The membrane attack complex is a protein complex of complement components C5b, C6, C7, C8, and C9 that inserts into target cell membranes and forms a pore, causing cell lysis via ion and water flow.
What genes are involved in the membrane attack complex?
The core genes are C5, C6, C7, C8A, C8B, C8G, and C9, with regulators such as CD59, clusterin, and vitronectin.
How is the membrane attack complex assembled?
It assembles sequentially: C5b binds C6 and C7, inserts into the membrane, recruits C8, and then multiple C9 molecules polymerize to form the pore.
What is the function of CD59 in MAC regulation?
CD59 binds C8 and C9 and blocks C9 polymerization, preventing MAC pore formation on host cells.
What diseases are associated with the membrane attack complex?
MAC is implicated in kidney disease, inflammatory and autoimmune disorders, and defense against Gram-negative bacteria.
What is soluble MAC (sC5b-9)?
Soluble MAC is the fluid-phase form of the terminal complement complex and is used as a biomarker of complement activation in plasma.
How can CRISPR be used to study the membrane attack complex?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of MAC components and regulators in human cells.
Which cells are best for MAC research?
Cells that are naturally exposed to complement, such as erythrocytes, kidney cells, and Gram-negative bacteria, are commonly used, along with engineered human cell lines.
What methods measure MAC activity?
ELISA for sC5b-9, flow cytometry, hemolytic assays, and bacterial killing assays are standard methods.
Is the membrane attack complex the same as terminal complement complex?
Yes, MAC and terminal complement complex (TCC) are synonyms for the same GO:0005579 entity.
Conclusion
The membrane attack complex (GO:0005579) is a sequentially assembled, pore-forming complement complex that is central to innate immunity and a driver of inflammatory tissue damage when dysregulated. Its components and regulators, including CD59, are well-defined and experimentally tractable. CRISPR-based knockout, knock-in, point mutation, and overexpression models provide powerful tools to dissect MAC biology and to identify therapeutic targets in complement-mediated diseases.
References
- 1. Barnum SR et al.. 2020. Soluble Membrane Attack Complex: Biochemistry and Immunobiology.. Front Immunol 11:585108 PMID: 33240274
- 2. Couves EC et al.. 2023. Structural basis for membrane attack complex inhibition by CD59.. Nat Commun 14(1):890 PMID: 36797260
- 3. Xie CB et al.. 2020. Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.. Am J Pathol 190(6):1138-1150 PMID: 32194049
- 4. Morgan BP. 2016. The membrane attack complex as an inflammatory trigger.. Immunobiology 221(6):747-51 PMID: 25956457
- 5. Koopman JJE et al.. 2020. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.. Front Immunol 11:599974 PMID: 33643288
- 6. Doorduijn DJ et al.. 2019. How the Membrane Attack Complex Damages the Bacterial Cell Envelope and Kills Gram-Negative Bacteria.. Bioessays 41(10):e1900074 PMID: 31452228
- 7. Müller-Eberhard HJ. 1984. The membrane attack complex.. Springer Semin Immunopathol 7(2-3):93-141 PMID: 6387983
- 8. Müller-Eberhard HJ. 1986. The membrane attack complex of complement.. Annu Rev Immunol 4:503-28 PMID: 3518749
